Literature DB >> 12745038

Beta-blocker use in the emergency department in patients with acute myocardial infarction undergoing primary angioplasty.

Diana Pancu1, David C Lee.   

Abstract

Our objectives were to evaluate the frequency of beta-blocker administration in the setting of acute myocardial infarction (AMI) where angioplasty is the primary treatment, and to investigate emergency physician's (EPs) attitudes toward beta-blockers. We performed a retrospective chart review of all patients who presented with symptoms and electrocardiogram (EKG) criteria consistent with AMI in the defined study period. Charts were reviewed for beta-blocker administration and other treatments. A survey was subsequently distributed to all EPs to determine self-reported reasons for withholding beta-blockers. There were 91 patients identified. Of those who did not have contraindications, 99% (89/90) received aspirin, 97% (88/91) received heparin, 94% (84/89) received nitrates, but only 28% (19/68) received beta-blockers. Ninety-six percent of beta-blocker-eligible patients received them as inpatients. Eighty-six percent (44/52) of EPs completed the survey. Physicians felt strongly about avoiding beta-blockers in patients with asthma exacerbation, severe congestive heart failure, and high degree AV block. Bradycardia was the most frequent reason for withholding beta-blockers. In this series of patients presenting with AMI, beta-blockers were greatly underutilized. The self-reported reasons of EPs for withholding beta-blocker therapy did not explain why 72% (49/68) of patients without contraindications did not receive beta-blockers.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12745038     DOI: 10.1016/s0736-4679(03)00033-7

Source DB:  PubMed          Journal:  J Emerg Med        ISSN: 0736-4679            Impact factor:   1.484


  1 in total

1.  Red blood cell transfusion practices in two surgical intensive care units: a mixed methods assessment of barriers to evidence-based practice.

Authors:  David J Murphy; Peter J Pronovost; Christoph U Lehmann; Ayse P Gurses; Glenn J R Whitman; Dale M Needham; Sean M Berenholtz
Journal:  Transfusion       Date:  2014-05-21       Impact factor: 3.157

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.